Brief: Hemostemix Announces U.S. FDA Clinical Trial Approval
19/04/2018 13:41
April 19 (Reuters) - Hemostemix Inc HEM.V :
* HEMOSTEMIX ANNOUNCES US FDA CLINICAL TRIAL APPROVAL
* HEMOSTEMIX INC - UNITED STATES FOOD AND DRUG
ADMINISTRATION HAS
RAISED NO OBJECTIONS TO COMPANY'S INVESTIGATIONAL NEW DRUG
APPLICATION
Source text for Eikon: ID:nGNX54J821
Further company coverage: HEM.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hemostemix
See all newsBrief: Hemostemix Announces Financing Update And Secured Convertible Debenture Financing Of Up To $2,000,000
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update